Abstract
Peptides and proteins have been known for more than a century, but was only when du Vigneaud published the first synthesis of oxytocin, that the research on bioactive peptides was truly launched. Since then, the scientific progresses in the field have been astonishing and the synthesis of peptides of virtually any size and complexity is now possible. Perhaps the most important milestone was the development of the solid-phase peptide synthesis (SPPS) by Merrifield (1963), to revolutionize the field. In this critic review, we will analyze how the SPPS contributed to widespread the manufacture of peptides as active pharmaceuticals and what will be the challenges of tomorrow in this field.
Keywords: SPPS, LPPS, fmoc-chemistry, molecular machine, native chemical ligation.
Current Bioactive Compounds
Title:The Evolution of Peptide Synthesis: From Early Days to Small Molecular Machines
Volume: 9 Issue: 3
Author(s): Adriano Mollica, Francesco Pinnen, Stefanucci Azzurra and Roberto Costante
Affiliation:
Keywords: SPPS, LPPS, fmoc-chemistry, molecular machine, native chemical ligation.
Abstract: Peptides and proteins have been known for more than a century, but was only when du Vigneaud published the first synthesis of oxytocin, that the research on bioactive peptides was truly launched. Since then, the scientific progresses in the field have been astonishing and the synthesis of peptides of virtually any size and complexity is now possible. Perhaps the most important milestone was the development of the solid-phase peptide synthesis (SPPS) by Merrifield (1963), to revolutionize the field. In this critic review, we will analyze how the SPPS contributed to widespread the manufacture of peptides as active pharmaceuticals and what will be the challenges of tomorrow in this field.
Export Options
About this article
Cite this article as:
Mollica Adriano, Pinnen Francesco, Azzurra Stefanucci and Costante Roberto, The Evolution of Peptide Synthesis: From Early Days to Small Molecular Machines, Current Bioactive Compounds 2013; 9 (3) . https://dx.doi.org/10.2174/157340720903140119151919
DOI https://dx.doi.org/10.2174/157340720903140119151919 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer
Current Cancer Drug Targets Prevalence and Associated Risk Factors of Hyperglycemia and Diabetes Mellitus Among HIV Positive Patients in Tehran, Iran
Infectious Disorders - Drug Targets Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Therapeutic Potential of Amniotic Fluid Stem Cells
Current Stem Cell Research & Therapy Podocytes as a Target of Prorenin in Diabetes
Current Diabetes Reviews Application of Nanohydrogels in Drug Delivery Systems: Recent Patents Review
Recent Patents on Nanotechnology Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer
Current Medicinal Chemistry Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management
Current Pharmaceutical Design Tissue Fatty Acid Profile is Differently Modulated from Olive Oil and Omega-3 Polyunsaturated Fatty Acids in ApcMin/+ Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Metabolic Routes in Inflammation: The Citrate Pathway and its Potential as Therapeutic Target
Current Medicinal Chemistry Acknowledgements to Reviewers
Current Diabetes Reviews Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets Gab1, SHP-2 and Other Novel Regulators of Ras: Targets for Anticancer Drug Discovery?
Current Cancer Drug Targets Prevalence of Diabetes Among Immigrants in the Nordic Countries
Current Diabetes Reviews Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?
Current Drug Safety